Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears

Boston,,Massachusetts;,July,7,,2017,:,Holding,A,Truvada,Prep

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday.

The HIV drug maker reported adjusted earnings of $2.01 per share, beating the consensus of $1.94. Sales reached $7.08 billion, beating the consensus of $6.94 billion.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.